# Phase 1/2 Carcinoma, Renal Cell trials recruiting: 42 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 42 trials in phase 1/2 for Carcinoma, Renal Cell that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 Carcinoma, Renal Cell trials: 42 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/carcinoma-renal-cell

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 42
- Recruiting or not yet: 42
- Read on: November 19, 2026

## Trials

The 25 newest of 42, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07933419 | Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid Tumors | Qilu Pharmaceutical Co., Ltd. | Phase 1/2 | Not yet recruiting | Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Other Advanced Solid Tumors | 558 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933419) |
| October 7, 2026 | NCT07863024 | Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET... | Regeneron Pharmaceuticals | Phase 1/2 | Recruiting | Advanced Solid Tumors | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07863024) |
| August 6, 2026 | NCT07749586 | A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors | Arvinas Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumor | 499 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07749586) |
| June 9, 2026 | NCT07636785 | A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors | VM Discovery, Inc. | Phase 1/2 | Recruiting | Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC), Nonsmall Cell Lung Cancer... | 111 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07636785) |
| May 18, 2026 | NCT07594106 | REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic... | Regeneron Pharmaceuticals | Phase 1/2 | Recruiting | Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) | 265 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07594106) |
| April 24, 2026 | NCT07551349 | Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma | Beijing Biotech | Phase 1/2 | Recruiting | Advanced or Metastatic Clear Cell Renal Cell Carcinoma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551349) |
| December 19, 2025 | NCT07293351 | A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With... | Bristol-Myers Squibb | Phase 1/2 | Recruiting | Advanced Renal Cell Carcinoma (RCC) | 474 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07293351) |
| November 12, 2025 | NCT07227415 | Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in... | Pfizer | Phase 1/2 | Recruiting | Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm, Clear Cell Renal Cell Carcinoma... | 224 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07227415) |
| October 22, 2025 | NCT07219576 | Retifanlimab and Ruxolitinib In Solid Malignancies | University of California, San Diego | Phase 1/2 | Recruiting | Non Small Cell Lung Carcinoma, Renal Cell Carcinoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07219576) |
| September 15, 2025 | NCT07172802 | A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors | GI Innovation, Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancer (NSCLC), Head and Neck (HNSCC), Pancreatic... | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07172802) |
| August 11, 2025 | NCT07115043 | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors | AstraZeneca | Phase 1/2 | Recruiting | Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07115043) |
| July 8, 2025 | NCT07053462 | CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk | AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC | Phase 1/2 | Recruiting | End-Stage Renal Disease, End Stage Renal Disease on Dialysis, End Stage Renal Disease With Renal Transplant, Kidney... | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07053462) |
| July 3, 2025 | NCT07049926 | Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After... | Merck Sharp & Dohme LLC | Phase 1/2 | Recruiting | Renal Cell Carcinoma | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07049926) |
| March 26, 2025 | NCT06896552 | Single-Center Trial on Ketogenic Diet and Immunotherapy in Advanced Cancer This Study Evaluates the Safety and Effects of a Ketogenic Diet... | Rabin Medical Center | Phase 1/2 | Not yet recruiting | Cancer, Immunotherapy, Ketogenic Diet | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06896552) |
| March 10, 2025 | NCT06866262 | Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial | University of Michigan Rogel Cancer Center | Phase 1/2 | Recruiting | Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear... | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06866262) |
| February 19, 2025 | NCT06835972 | A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC) | Memorial Sloan Kettering Cancer Center | Phase 1/2 | Recruiting | Metastatic Renal Cell Carcinoma, Translocation Renal Cell Carcinoma | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06835972) |
| December 27, 2024 | NCT06750185 | Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors | BioNTech SE | Phase 1/2 | Recruiting | Advanced Solid Tumor | 248 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06750185) |
| August 29, 2024 | NCT06577961 | Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 1/2 | Not yet recruiting | Kidney Cancer, RCC, Renal Cell Carcinoma | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06577961) |
| June 25, 2024 | NCT06472895 | A Study of AK112 Monotherapy in Advanced/Metastatic Renal Cell Carcinoma | Peking University Cancer Hospital & Institute | Phase 1/2 | Not yet recruiting | Renal Cell Carcinoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06472895) |
| May 29, 2024 | NCT06432036 | Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial | Jonsson Comprehensive Cancer Center | Phase 1/2 | Recruiting | Stage I Renal Cell Cancer, Stage II Renal Cell Cancer | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06432036) |
| May 14, 2024 | NCT06413680 | A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult... | Regeneron Pharmaceuticals | Phase 1/2 | Recruiting | Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06413680) |
| April 12, 2024 | NCT06362369 | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | 7 Hills Pharma, LLC | Phase 1/2 | Recruiting | Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis, Pleural Mesothelioma, Renal Cell Carcinoma, MSI-High... | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06362369) |
| February 20, 2024 | NCT06265025 | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | GeneMedicine Co., Ltd. | Phase 1/2 | Recruiting | Head and Neck Cancer, Malignant Melanoma, Colorectal Cancer, Renal Cell Carcinoma, Cervical Cancer, Breast Cancer | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06265025) |
| January 24, 2024 | NCT06222593 | Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC | State University of New York at Buffalo | Phase 1/2 | Recruiting | Carcinoma, Renal Cell | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06222593) |
| September 21, 2023 | NCT06047379 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | Neonc Technologies, Inc. | Phase 1/2 | Recruiting | Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal... | 134 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06047379) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 4 |
| GI Innovation, Inc. | 3 |
| National Cancer Institute (NCI) | 2 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 2 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| Jonsson Comprehensive Cancer Center | 1 |
| Shanghai Public Health Clinical Center | 1 |
| University of Michigan Rogel Cancer Center | 1 |
| Arvinas Inc. | 1 |
| Portage Biotech | 1 |
| Neonc Technologies, Inc. | 1 |
| VM Discovery, Inc. | 1 |
| Inhibrx Biosciences, Inc | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| [BioNTech SE](https://specstream.ai/data/clinical-trials/company/biontech-se) | 1 |
| M.D. Anderson Cancer Center | 1 |
| GeneMedicine Co., Ltd. | 1 |
| State University of New York at Buffalo | 1 |
| [Qilu Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd) | 1 |
| Aulos Bioscience, Inc. | 1 |
| Simcha IL-18, Inc. | 1 |
| Rabin Medical Center | 1 |
| University of California, San Diego | 1 |
| AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC | 1 |
| Scancell Ltd | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 30 |
| South Korea | 9 |
| Australia | 7 |
| China | 7 |
| Spain | 5 |
| Japan | 4 |
| France | 4 |
| Germany | 3 |
| United Kingdom | 3 |
| Israel | 3 |
| Canada | 2 |
| Chile | 2 |
| Italy | 2 |
| Singapore | 1 |
| Taiwan | 1 |
| Argentina | 1 |
| Colombia | 1 |
| Czechia | 1 |
| Finland | 1 |
| Ireland | 1 |
| Mexico | 1 |
| Romania | 1 |
| Switzerland | 1 |
| Poland | 1 |
| Portugal | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Fence contractors in the United States](https://specstream.ai/data/businesses/fence-contractors/united-states)
- [B2B domestic trade companies in the United States](https://specstream.ai/data/businesses/b2b-domestic-trade-companies/united-states)
- [Radiology practices in the United States](https://specstream.ai/data/businesses/radiology-practices/united-states)
- [Hot dog restaurants in the United States](https://specstream.ai/data/businesses/hot-dog-restaurants/united-states)
- [Cafeterias in the United States](https://specstream.ai/data/businesses/cafeterias/united-states)
- [Surgery practices in the United States](https://specstream.ai/data/businesses/surgery-practices/united-states)
